Bringing transformational treatments to patients sooner
Applying integrated and efficient translational science to develop new treatments that help combat and cure diseases.
Our Pipeline
Our extensive experience and unique drug development engine enable us to identify and incubate high-potential novel drug candidates and rapidly deliver partner-ready clinical assets. Our lead technology platform is our proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP), which can be applied across multiple therapy areas and indications. PDSP is a multifunctional secreted protein that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. This platform opens up exciting possibilities for wound healing and tissue regeneration due to its ability to enhance cell proliferation.
Worldwide license for developing PDSP
In 2015, BRIM was granted an exclusive, worldwide license for developing PDSP in all therapeutic indications including dry eye syndrome, corneal wound healing, diabetic ulcer wound healing, osteoarthritis, androgenic alopecia, and muscle/tendon regeneration.
Our lead assets
Our lead asset, BRM421, is on track to become a first-in-class treatment for dry eye syndrome (DES) which treats and repairs cornea damage. BRM421 has demonstrated safety and efficacy in two clinical studies. BRIM is devoted to the development of other novel synthetic peptides, including treatments for severe corneal damage (BRM423), and osteoarthritis (BRM521).
Dry Eye Syndrome
A potential first-in-class treatment for Dry Eye Syndrome (DES) which treats and repairs corneal damage.
Severe Cornea Damage
Targeted to treat severe cornea damage which can lead to blindness.
Neurotrophic Keratitis(NK)
Early-stage treatment in development for Neurotrophic Keratitis (NK), a rare, degenerative disease affecting the cornea.
Osteoarthritis
Unique mechanism of action promotes joint cartilage regeneration and relieves pain caused by osteoarthritis.
Awards
2018 Drug R&D Awards
Silver Prize In Drug Development
This Award was given by the Taiwan Ministry of Health and Welfare and the Ministry of Economic Affairs. It is the only biotechnology related award from governmental service. This Award recognizes that BRM421 for Dry Eye Disease is a first-in-class new drug that is effective in corneal repairing.
2019 Prominent Enterprise Awards
Outstanding Fundraising Award
The Taipei Prominent Enterprise Awards were designed to recognize and encourage outstanding enterprise achievements in innovation, competitiveness, market power, influence on the overall industry, economy and society, and impact on social responsibility.
2020 Taiwan BIO Awards
Outstanding Potential Award
Drug/Cell Therapeutic Area
BRIM’s professional expertise in translational sciences, virtual business model, and ability to develop new drugs were recognized by this award as one of the five most outstanding potential biotech companies.
2020 Taipei Biotech Awards
Innovative Technology Award – First Prize
The Taipei Biotech Awards encourage further investment in the field of biotech research and development. BRIM’s PDSP technology platform was the first prize winner of the “Innovative Technology Award.”
News
I was impressed with BRIM’s innovation and the unique mechanism of action of their lead compound in treating Dry Eye Disease.
Bob Ruffolo
BRIM Scientific Board Member and former president of R&D at Wyeth Pharmaceuticals
I was impressed with BRIM’s innovation and the unique mechanism of action of their lead compound in treating Dry Eye Disease.
Bob Ruffolo
BRIM Scientific Board Member and former president of R&D at Wyeth Pharmaceuticals
Download BRIM’s corporate factsheet
Find out more about our product pipeline and development milestones.
Download BRIM’s Corporate Overview
